Rogaratinib (BAY1163877) is being evaluated in a Phase 1 clinical trial targeting FGFR-positive refractory, locally advanced, or metastatic solid tumors in Chinese patients. Given the increasing prevalence of FGFR mutations in various cancers, this asset has the potential to address a significant unmet medical need in oncology. The trial's completion in April 2020 positions Bayer to leverage the data for potential regulatory submissions or partnerships, particularly in the Asian market where FGFR-targeted therapies are underrepresented. Competitive analysis indicates that while there are existing FGFR inhibitors, the unique pharmacokinetic profile of rogaratinib may provide a differentiated therapeutic option. Diligence should focus on the safety and tolerability data, as well as the pharmacokinetic outcomes, to assess the viability for further development or commercialization.